Antisense Therapeutics Limited (ASX:ANP)


right-arrow Created with Sketch. 0 (0%)
MCAP $117.0M
Last trade 16.10pm 27/01/2022 20mins delayed

Latest Announcements

16.17pm 27/01/2022ANPAntisense Therapeutics Limited
09.11am 27/01/2022 Price SensitivePSANPAntisense Therapeutics Limited
24/12/2021ANPAntisense Therapeutics Limited
24/12/2021ANPAntisense Therapeutics Limited
23/12/2021ANPAntisense Therapeutics Limited
22/12/2021ANPAntisense Therapeutics Limited
22/12/2021ANPAntisense Therapeutics Limited
22/12/2021ANPAntisense Therapeutics Limited

Company Overview

Antisense Therapeutics Limited is an Australia-based biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly. The Company's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company is engaged in clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.

ANP in the news

Antisense Therapeutics (ANP) has raised just under $2.6 million from an entitlement…
Antisense Therapeutics (ANP) receives a positive decision for the UK Paediatric Investigation…
Antisense Therapeutics (ANP) has submitted its ATL1102 inhibitor toxicology protocol to the…
The Paediatric Committee (PDCO) of the European Medicines Agency (EMA) has given…

Search Previous Announcements